does melanotan 2: Frequently asked questions

Spontaneous erections unrelated to sexual context occurred in 22% of trial participants. This is the central mechanism at work. Unlike PDE5 inhibitors, MT-2 doesn't require arousal to produce an erectile response. The effect lasts 6–8 hours post-injection, so timing administration matters. Injecting before bed reduces daytime inconvenience but may disrupt sleep. Cold water immersion or physical exertion can temporarily reduce tumescence through sympathetic nervous system activation, but the effect returns once adrenergic tone drops.

Verify peptide purity and reconstitution accuracy first. Underdosed or improperly stored melanotan-2 loses potency rapidly. If using a research-grade product from a verified source, increase the dose by 1–2mg increments at 48-hour intervals until effect is observed or nausea becomes limiting. Clinical trials show significant inter-individual variation in receptor sensitivity. Some participants required 15mg to achieve the same arousal response others experienced at 7.5mg. Doses above 20mg are not supported by safety data.

Document changes photographically at each session but recognize this is an expected melanogenic effect from MC1R activation, not an adverse event requiring discontinuation unless pre-existing melanoma risk factors are present. The darkening is reversible over weeks to months post-study, though complete return to baseline pigmentation can take six to twelve months. Exclude participants with dysplastic nevi or personal/family history of melanoma from protocols to avoid ethical and safety concerns around cumulative melanocyte stimulation.

Administer MT-2 in the evening with light food intake and provide ondansetron (Zofran) 4–8 mg orally 30 minutes before dosing. Nausea from melanocortin activation is mediated by area postrema stimulation in the brainstem. Anti-emetic premedication blunts this without interfering with MC4R-driven sexual arousal pathways. Alternatively, reduce the dose to 0.5 mg and extend the titration schedule over additional sessions to allow physiological adaptation. Most participants develop tolerance to nausea after three to five doses.

Reduce the next dose by 50% and split it into two administrations 8–12 hours apart. Nausea from melanotan-2 peaks 2–4 hours post-injection and resolves within 6–8 hours. Splitting the dose reduces peak plasma concentration without sacrificing total exposure. Pre-dosing with 10mg ondansetron (Zofran) 30 minutes before injection significantly reduces nausea incidence in clinical protocols. If nausea persists at reduced doses, the compound may not be tolerable. MC4R activation in the brainstem's chemoreceptor trigger zone is dose-dependent but not avoidable.

Increase the dose incrementally to 1.5–2 mg on subsequent administrations if initial dosing was at 0.5–1 mg. Individual variability in MC4R receptor density and hypothalamic sensitivity means some participants require higher doses to reach threshold activation. If no response occurs at 2 mg subcutaneous dosing after two trials, consider that the participant may have organic rather than psychogenic ED. Peripheral vascular or neurological deficits won't respond to central melanocortin activation. Stratify participants based on ED aetiology before concluding non-response.

This is the expected pharmacological effect. MC4R and MC1R activation occur simultaneously because melanotan-2 is non-selective between receptor subtypes. You cannot isolate the pigmentation effect without the arousal effect using MT-2. If the arousal side effects are unwanted, consider melanotan-1 (afamelanotide), which has higher selectivity for MC1R and minimal MC4R activity. Though it's significantly less effective for tanning and requires higher doses.

MT-2 produced responses in 64% of sildenafil non-responders in the 2003 European Urology trial, but success depends on why sildenafil failed. If the issue is psychogenic (performance anxiety, stress-related arousal disruption), MT-2 addresses the central deficit directly. If the issue is severe vascular disease (atherosclerotic plaques blocking penile arteries), neither drug will work. The mechanical obstruction prevents blood flow regardless of signaling. Nocturnal penile tumescence testing distinguishes these: normal nocturnal erections indicate intact vasculature, suggesting MT-2 is worth trialing.

Nausea occurs in 40–50% of first-time users due to melanocortin activation in the area postrema (the brain's vomiting centre). It typically resolves by the third or fourth dose as receptor desensitisation occurs. Taking MT-2 in the evening on an empty stomach reduces severity. Eating within two hours of injection worsens GI symptoms. If nausea persists beyond five administrations, lowering the dose to 0.025mg/kg often eliminates it while retaining erectile benefit. Antiemetics like ondansetron are rarely necessary but can be used if symptoms are intolerable.

Dose requirements for female sexual arousal may differ from male protocols. The 2008 bremelanotide trial in women used 1.25–1.75 mg doses to achieve statistical significance, compared to 0.5–1.0 mg typical in male erectile dysfunction studies. Female sexual response also shows higher placebo rates (15–20% vs 5–10% in men), requiring larger sample sizes to detect treatment effect. Reassess dosing and consider extending observation windows. Female arousal metrics are more subjective and may require multiple dosing sessions before reaching statistical significance.

Seek immediate medical evaluation. Prolonged erection (priapism) can cause permanent damage to erectile tissue if untreated beyond 4–6 hours. Melanotan-2-induced priapism is rare (fewer than 2% of research subjects) but occurs most often at doses above 2mg subcutaneous or 15mg intranasal. Emergency treatment typically involves aspiration of blood from the corpora cavernosa with or without injection of phenylephrine to induce detumescence. Unlike PDE5 inhibitor-related priapism, melanocortin-mediated erections may not respond to standard sympathomimetic agents because the mechanism bypasses the nitric oxide pathway entirely.

Melanotan-2's plasma half-life is approximately 33 minutes, but MC4R receptor activation can persist for 12–24 hours after a single dose due to prolonged receptor occupancy. This is a known effect, not an adverse event. Participants should be informed during consent that sexual thoughts and spontaneous arousal may continue beyond the planned observation window. No medical intervention is required. The effect resolves as receptor binding dissipates naturally.

Non-responsiveness suggests MC1R dysfunction, which occurs in certain pigmentary disorders and red-haired phenotypes (MC1R variant alleles). Verify receptor expression via qPCR or immunofluorescence staining. If MC1R is present but non-functional, test downstream pathway components. Adenylyl cyclase activation with forskolin, cAMP levels directly, or tyrosinase expression independent of receptor signaling. MT-II resistance is itself a research finding relevant to vitiligo and melanoma studies.

Administer MT-II subcutaneously at 1–10 mg/kg (dose-dependent on species) and compare pigmentation density, melanin distribution in hair follicles, and UV damage markers after controlled UV exposure. The key metric is whether MT-II-induced pigmentation provides equivalent photoprotection to UV-induced tanning. Current evidence suggests partial but not complete equivalence, possibly due to differences in melanin polymer structure or melanosome transfer efficiency.

Check MC1R expression levels in your melanocyte line first. Some immortalised lines downregulate MC1R after extended passage. If MC1R expression is confirmed, the issue is likely peptide potency or preparation error. Re-verify peptide concentration using a spectrophotometer (MT2 has an extinction coefficient of ~5,500 M⁻¹cm⁻¹ at 280 nm). If concentration is correct, request a replacement vial and independent HPLC verification from your supplier.

Dose MT2 based on molarity, not mass, and confirm accurate serial dilution at each step. Pigmentation variability often traces back to pipetting errors during stock solution preparation. For in vivo models, subcutaneous injection depth and volume also matter. Injections too shallow (intradermal) or too deep (intramuscular) alter absorption kinetics. Standardise injection sites, needle gauge (27G or finer), and injection volume (≤0.2 mL per site for rodents).

Freezing reconstituted peptides causes ice crystal formation that physically disrupts peptide structure. Frozen water expands, shearing peptide molecules and accelerating aggregation when thawed. If a reconstituted vial froze solid, discard it. The peptide conformation won't recover. Unreconstituted lyophilised Melanotan-2 tolerates freezing (−20°C storage is actually ideal for long-term preservation), but once in solution, freezing is destructive. Set your refrigerator to 4–6°C and store peptide vials away from the rear wall where cold spots occur.

No published human data exists on combined use, but animal models suggest additive or synergistic effects on erectile rigidity. The mechanisms operate on different pathways (melanocortin receptor vs nitric oxide signaling), so pharmacological interaction risk is low. The primary concern is cumulative vasodilation causing hypotension. Both compounds can lower blood pressure through different mechanisms. If combining experimentally, reduce doses of both compounds below standard monotherapy levels and monitor for dizziness, lightheadedness, or syncope. We've reviewed case reports where researchers used 50–75% of standard doses for each compound together without adverse cardiovascular events, but this remains unstudied in controlled trials.

Refrigerate it immediately and reduce your expected potency by 10–15% if the ambient temperature was below 22°C for fewer than 12 hours. If the vial was exposed to temperatures above 25°C (common in summer or near heat sources) for 8+ hours, peptide bond hydrolysis has likely exceeded 20%, and the solution should be discarded. Partial degradation doesn't produce half-strength doses; it produces unpredictable receptor binding with inconsistent melanogenesis. There's no reliable way to measure remaining potency at home; err on the side of disposal rather than injecting a solution with unknown activity.

Current Melanotan-2 formulations can't achieve this—MC1R and MC4R binding occur at overlapping dose ranges. Researchers pursuing appetite-specific effects use MC4R-selective agonists under development (like setmelanotide, which has FDA approval for rare genetic obesity) or compare Melanotan-2 effects to vehicle controls that include MC1R-selective antagonists. The alternative is accepting pigmentation as a secondary endpoint and monitoring it as part of the study design rather than attempting to eliminate it.